How to deal with capmatinib resistance?

Capmatinib resistance is a complex and common phenomenon during treatment. Drug resistance means that the inhibitory effect of drugs on cancer cells gradually weakens, resulting in treatment failure. Strategies for managing capmatinib resistance need to be tailored to the patient's specific circumstances, including consideration of the molecular characteristics of the tumor, the patient's overall health, and available treatment options. Here are some possible solutions:

1.Confirm resistance: Before formulating a treatment plan, it is first necessary to ensure that the patient is actually resistant to capmatinib. This is usually carried out through the observation of clinical symptoms, imaging examinations (such as CTscan or PETscan), and blood biochemical indicators. Confirmation of drug resistance is the basis for developing next-step treatment plans.

2.Molecular biology testing: Molecular biology testing of patients' tumors, including analysis of gene mutations, protein expression and other molecular characteristics, can provide important information about the mechanism of drug resistance. This facilitates the development of individualized treatment strategies.

3.Combination therapy: One strategy is to try to combine capmatinib with other targeted drugs to enhance the therapeutic effect. This may involve using different targeted therapies simultaneously or alternately to inhibit multiple cancer signaling pathways.

4.Change the treatment plan: Consider changing to other targeted drugs or immunotherapy drugs. There may be other options for targeted therapies for patients with METexon14skipping mutation non-small cell lung cancer (NSCLC). In addition, immunotherapy is an option worth considering, especially when targeted therapies fail.

5.Clinical trials: Participating in clinical trials is a way to try new treatment strategies. When treating resistance, some new experimental drugs or treatment regimens may be being tested in clinical trials, and patients can gain access to new treatment opportunities by participating in these trials.

6.Supportive treatment: If the effect of cancer treatment is limited, doctors may take some supportive treatment measures to help relieve the patient's symptoms and improve the quality of life, including pain management, nutritional support, etc.

7.Regular monitoring and adjustment: After adopting a new treatment plan, it is crucial to regularly monitor changes in the patient's condition. Depending on the patient's response, doctors may need to adjust the treatment plan for optimal results.

8.Comprehensive treatment team: The management of capmatinib resistance requires a comprehensive treatment team, including oncologists, radiation oncologists, clinical pharmacists, nutritionists, etc., to develop an individualized treatment plan.

Overall, management of capmatinib resistance requires an individualized, multidisciplinary approach. Doctors should develop the most appropriate treatment plan based on the patient's condition, tumor characteristics, and treatment response, while focusing on the patient's quality of life and comprehensive supportive treatment. This also emphasizes the importance of personalized medicine and precision medicine in cancer treatment.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.